JF
ADCT icon

Jump Financial’s ADC Therapeutics ADCT Stock Holding History

Jump Financial’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$121K Sell
32,230
-130,020
-80% -$513K ﹤0.01% 1733
2025
Q4 		$573K Buy
162,250
+150,659
+1,300% +$611K 0.01% 1262
2025
Q3 		$46.4K Buy
+11,591
New +$36.5K ﹤0.01% 1705

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jump Financial's ADCT Position: Q1 2026 in Review

Jump Financial reduced its ADC Therapeutics (ADCT) stake by 80% in Q1 2026, selling an estimated $513K and leaving 32,230 shares worth $121K. The position accounts for ﹤0.01% of the portfolio, ranked #1733.

Jump Financial first reported a position in ADCT in Q3 2025 and has held it in 3 quarters since. The position peaked at $573K in Q4 2025. 118 funds tracked by Wall St. Rank hold ADCT as of Q1 2026.

  • Jump Financial held 32,230 shares of ADC Therapeutics worth $121K as of Q1 2026.
  • Jump Financial sold 130,020 ADC Therapeutics shares in Q1 2026, an estimated $513K.
  • ADC Therapeutics made up ﹤0.01% of Jump Financial's portfolio in Q1 2026, its #1733 holding.
  • Jump Financial first reported a position in ADC Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Jump Financial's ADC Therapeutics position peaked at $573K in Q4 2025.
  • 118 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2026.

Based on Jump Financial's 13F filing for Q1 2026, filed 14 May 2026.